Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 5,448 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Control Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers

NCT02572349
View directory record Official record
Conditions
Healthy
Interventions
IW-1701, Matching Placebo
Drug
Lead sponsor
Cyclerion Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 20, 2026, 3:51 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Papulopustular Rosacea Study

NCT01493687
View directory record Official record
Conditions
Papulopustular Rosacea (PPR)
Interventions
CD5024, Azelaic acid 15% Gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
40
States / cities
Birmingham, Alabama • Rogers, Arkansas • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 20, 2026, 3:51 PM EDT
Completed Phase 2 Interventional Results available

Safety Study of Ivacaftor in Subjects With Cystic Fibrosis

NCT00457821
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor 25 mg/75 mg, Ivacaftor 75 mg/150 mg, Ivacaftor 150 mg or 250 mg, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 20, 2026, 3:51 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis

NCT02943447
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Cilofexor, Placebo to match cilofexor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
13
States / cities
Sacramento, California • Aurora, Colorado • Lakewood Rch, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 20, 2026, 3:51 PM EDT
Recruiting Phase 1 Interventional

A Study of PATAS Using Single Ascending Doses in Healthy Volunteers and Multiple Ascending Doses in Diabetic Subjects

NCT07223333
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
PATAS Trifluoroacetate, Placebo
Drug
Lead sponsor
AdipoPharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Chandler, Arizona • Miami, Florida • Port Orange, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 20, 2026, 3:51 PM EDT
Terminated Phase 4 Interventional Results available

Phase 4 Study in Adult Subjects Undergoing Posterior Lumbar Spine Surgeries

NCT03927911
View directory record Official record
Conditions
Postoperative Pain Management
Interventions
EXPAREL and Bupivacaine, Standard of Care
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
New Haven, Connecticut • Boca Raton, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 20, 2026, 3:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

OTO-313 in Subjects With Subjective Tinnitus

NCT03918109
View directory record Official record
Conditions
Tinnitus, Subjective
Interventions
OTO-313, Placebo
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • Colorado Springs, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 20, 2026, 3:51 PM EDT
Completed Phase 4 Interventional Results available

FS-67 in the Treatment of Pediatric Patients With Ankle Sprain

NCT01037816
View directory record Official record
Conditions
Ankle Sprain
Interventions
FS-67 Patch, Placebo Patch
Drug · Other
Lead sponsor
Hisamitsu Pharmaceutical Co., Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 20, 2026, 3:51 PM EDT
Completed Phase 2 Interventional Results available

Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease

NCT02947893
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo Capsule(s) Once a Day by Mouth, Nilotinib Capsule(s) Once a Day by Mouth
Drug
Lead sponsor
Georgetown University
Other
Eligibility
50 Years to 85 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 20, 2026, 3:51 PM EDT
Recruiting Phase 3 Interventional

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

NCT05232916
View directory record Official record
Conditions
Breast Cancer
Interventions
Placebo, GLSI-100
Biological
Lead sponsor
Greenwich LifeSciences, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
2,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
51
States / cities
Mobile, Alabama • Goodyear, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 20, 2026, 3:51 PM EDT
Completed Phase 2 Interventional Results available

Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)

NCT01894516
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GLPG0634, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
21
States / cities
Gilbert, Arizona • Mesa, Arizona • Phoenix, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 20, 2026, 3:51 PM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT06161571
View directory record Official record
Conditions
NASH/MASH, NAFLD/MASLD
Interventions
Efruxifermin, Placebo
Drug
Lead sponsor
Akero Therapeutics, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
139
States / cities
Birmingham, Alabama • Chandler, Arizona • Flagstaff, Arizona + 117 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 20, 2026, 3:51 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy

NCT03283371
View directory record Official record
Conditions
Epilepsy, Focal Seizures, Partial Seizures
Interventions
Natalizumab, Placebo
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 20, 2026, 3:51 PM EDT
Completed Phase 3 Interventional Results available

Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)

NCT00288704
View directory record Official record
Conditions
Familial Cold Autoinflammatory Syndrome (FCAS), Familial Cold Urticaria, Muckle-Wells Syndrome (MWS), Genetic Diseases, Inborn
Interventions
rilonacept 160 mg, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
7 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
24
States / cities
Little Rock, Arkansas • Palm Desert, California • Upland, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Oct 20, 2026, 3:51 PM EDT
Completed Phase 2 Interventional

Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder

NCT05536414
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Centanafadine, Escitalopram, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
62
States / cities
Yuma, Arizona • Bryant, Arkansas • Glendale, California + 53 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 20, 2026, 3:51 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease

NCT04026165
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
SEL, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
71
States / cities
Glendale, Arizona • Tucson, Arizona • Canyon Country, California + 59 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 20, 2026, 3:51 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris

NCT01631474
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CB-03-01, Vehicle
Drug
Lead sponsor
Intrepid Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Sanford, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 20, 2026, 3:51 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Effects of Aquamin F on NSAID Dose Reduction in Osteoarthritis of the Knee

NCT00755482
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Aquamin F, Placebo (maltodextran)
Drug
Lead sponsor
Marigot Ltd.
Industry
Eligibility
35 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Edina, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 19, 2008 · Synced Oct 20, 2026, 3:51 PM EDT
Terminated Phase 2 Interventional Results available

Merotocin in Mothers With Inadequate Milk Production and Infants Delivered Prematurely

NCT02545127
View directory record Official record
Conditions
Preterm Delivery, Inadequate Milk Production
Interventions
Merotocin, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 44 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
New Haven, Connecticut • South Bend, Indiana • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 20, 2026, 3:51 PM EDT
Recruiting Phase 2Phase 3 Interventional

Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema

NCT07592273
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Surabgene Lomparvovec, Sham, Topical Steroid, Artificial Tears
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
37
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 3:51 PM EDT
Terminated Phase 2 Interventional

Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis

NCT05048056
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, AK120
Drug
Lead sponsor
Akesobio Australia Pty Ltd
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
16
States / cities
Little Rock, Arkansas • Canoga Park, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 20, 2026, 3:51 PM EDT
Terminated Phase 3 Interventional Results available

A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease

NCT02956486
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Elenbecestat, Placebo
Drug
Lead sponsor
Eisai Co., Ltd.
Industry
Eligibility
50 Years to 85 Years
Enrollment
2,212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
88
States / cities
Chandler, Arizona • Colton, California • Costa Mesa, California + 68 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 20, 2026, 3:51 PM EDT
Completed Phase 2 Interventional

A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients

NCT00001086
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
55
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 20, 2026, 3:51 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsy

NCT02201251
View directory record Official record
Conditions
Epilepsy
Interventions
Topiramate, Levetiracetam
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 15 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Gulf Breeze, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 20, 2026, 3:51 PM EDT